Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 900 of 2026 entries
View as:

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT06961370 Org: User:
Start: 06/30/25 End: 01/03/27 Due: 01/03/28

A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.

Phase: N/A Priority: Normal
NCT ID: NCT00717314 Org: User:
Start: 05/31/08 End: 07/31/11 Due: 07/31/12

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.

Phase: N/A Priority: Normal
NCT ID: NCT00717821 Org: User:
Start: 08/31/08 End: 07/31/11 Due: 07/31/12

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT04629248 Org: User:
Start: 06/25/21 End: 12/29/27 Due: 12/29/28

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

Phase: N/A Priority: Normal
NCT ID: NCT02165332 Org: User:
Start: 07/31/14 End: 11/30/14 Due: 11/30/15

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

Phase: N/A Priority: Normal
NCT ID: NCT00475072 Org: User:
Start: 06/30/03 End: 07/31/06 Due: 07/31/07

An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

Phase: N/A Priority: Normal
NCT ID: NCT03202368 Org: User:
Start: 10/25/17 End: 08/21/19 Due: 08/21/20

A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02825940 Org: User:
Start: 08/04/16 End: 11/04/22 Due: 11/04/23

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

Phase: N/A Priority: Normal
NCT ID: NCT02573012 Org: User:
Start: 03/29/16 End: 02/09/18 Due: 02/09/19

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

Phase: N/A Priority: Normal
NCT ID: NCT03261037 Org: User:
Start: 12/25/17 End: 11/27/19 Due: 11/27/20

A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00887822 Org: User:
Start: 03/31/09 End: 08/31/14 Due: 08/31/15

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00009737 Org: User:
Start: 11/30/98 End: 04/30/04 Due: 04/30/05

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT02247479 Org: User:
Start: 09/18/14 End: 01/29/18 Due: 01/29/19

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage

Phase: N/A Priority: Normal
NCT ID: NCT01661140 Org: User:
Start: 09/30/12 End: 02/28/15 Due: 02/28/16

A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01701739 Org: User:
Start: 10/31/12 End: 01/31/13 Due: 01/31/14

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Phase: N/A Priority: Normal
NCT ID: NCT06450639 Org: User:
Start: 04/04/25 End: 11/15/27 Due: 11/15/28

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05091424 Org: User:
Start: 03/07/22 End: 02/28/30 Due: 02/28/31

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT04576455 Org: User:
Start: 11/27/20 End: 06/27/25 Due: 06/27/26

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT05808764 Org: User:
Start: 04/26/24 End: 10/30/25 Due: 10/30/26

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05789082 Org: User:
Start: 06/20/23 End: 05/20/27 Due: 05/20/28

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06819891 Org: User:
Start: 05/12/25 End: 12/31/28 Due: 12/31/29

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT06819878 Org: User:
Start: 03/17/25 End: 12/31/33 Due: 12/31/34

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

Phase: N/A Priority: Normal
NCT ID: NCT06667414 Org: User:
Start: 09/02/24 End: 09/24/28 Due: 09/24/29

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT06624059 Org: User:
Start: 11/18/24 End: 03/31/33 Due: 03/31/34

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Phase: N/A Priority: Normal
NCT ID: NCT06439576 Org: User:
Start: 05/09/24 End: 11/30/27 Due: 11/30/28